netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Results

Looking for Tofacitinib found 13 matches
Open monograph to display formulary status BNF Category
  Tofacitinib  (Xeljanz®)
(See 10.01.03 Drugs which suppress the rheumatic disease process) 		Gastro-intestinal system - Drugs affecting the immune response - 01.05.03
  Tofacitinib  (Xeljanz®) Musculoskeletal and joint diseases - Drugs which suppress the rheumatic disease process - 10.01.03
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section MHRA Drug Safety Alert March 2020: Tofacitinib (Xeljanz▼): new measures to minimise risk of venous thromboembolism and of serious and fatal infections (01.05.03)
link in drug section MHRA Drug Safety Alert Oct 2021: Tofacitinib (Xeljanz▼): new measures to minimise risk of major adverse cardiovascular events and malignancies (01.05.03)
link in drug section MHRA Drug Safety Update (Mar 2020): Tofacitinib (Xeljanz▼): new measures to minimise risk of venous thromboembolism and of serious and fatal infections (10.01.03)
link in drug section MHRA Drug Safety Update (May 2019): Tofacitinib (Xeljanz▼): restriction of 10 mg twice-daily dose in patients at high risk of pulmonary embolism while safety review is ongoing (10.01.03)
link in drug section MHRA Drug Safety Update May 2019: Tofacitinib (Xeljanz▼): restriction of 10 mg twice-daily dose in patients at high risk of pulmonary embolism while safety review is ongoing (01.05.03)
link in drug section NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis Technology appraisal guidance  (10.01.03)
link in drug section NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (10.01.03)
link in drug section NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis (10.01.03)
link in drug section NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis (01.05.03)
link in drug section NICE TA735: Tofacitinib for treating juvenile idiopathic arthritis (10.01.03)
link in drug section NICE TA920: Tofacitinib for treating active ankylosing spondylitis (10.01.03)


 
netFormulary